FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225140897> ?p ?o ?g. }

• W4225140897 abstract "Coronary artery disease (CAD) is one of the leading causes of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM), who are at a greater risk of acute myocardial infarction (AMI) and sudden cardiac death. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce cardiovascular events and mortality in T2DM patients with a risk of cardiovascular disease. This study aimed to investigate the effect of SGLT2 inhibitor use on the adverse cardiovascular and renal outcomes in T2DM patients with AMI.A total of 1,268 patients admitted to the Coronary Care Unit due to AMI were retrospectively screened.Patients taking SGLT2 inhibitors before or during the index AMI hospitalization were assigned as group 1. Patients who never received SGLT2 inhibitors were assigned as group 2. Patients in groups 1 and 2 were matched in a 1:2 ratio, and 198 T2DM patients with stabilized AMI were retrospectively enrolled for the final analysis.With a mean follow-up period of 23.5 ± 15.7 months, 3 (4.5%) patients in group 1 and 22 (16.7%) patients in group 2 experienced rehospitalization for acute coronary syndrome (ACS), while 1 (1.5%) patient in group 1 and 7 (5.3%) patients in group 2 suffered sudden cardiac death. The Kaplan-Meier curves demonstrated that the patients in group 1 had a lower risk of adverse cardiovascular outcomes. According to the multivariate analysis, the baseline estimated glomerular filtration rate (eGFR) (P = 0.008, 95% CI: 0.944-0.991) and the use of SGLT2 inhibitors (P = 0.039, 95% CI: 0.116-0.947) were both independent predictors of adverse cardiovascular outcomes. On the other hand, the use of SGLT2 inhibitors was not associated with adverse renal outcomes.In T2DM patients with stabilized AMI, the use of SGLT2 inhibitors was associated with a lower risk of adverse cardiovascular outcomes. In addition, the baseline renal function was also an independent predictor of adverse cardiovascular outcomes." @default.
• W4225140897 created "2022-05-01" @default.
• W4225140897 creator A5001114263 @default.
• W4225140897 creator A5003828153 @default.
• W4225140897 creator A5025238832 @default.
• W4225140897 creator A5029430641 @default.
• W4225140897 creator A5038766995 @default.
• W4225140897 creator A5039171536 @default.
• W4225140897 creator A5060537275 @default.
• W4225140897 creator A5074831686 @default.
• W4225140897 date "2022-04-29" @default.
• W4225140897 modified "2023-10-17" @default.
• W4225140897 title "Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study" @default.
• W4225140897 cites W1974991340 @default.
• W4225140897 cites W2017106258 @default.
• W4225140897 cites W2026202984 @default.
• W4225140897 cites W2036876430 @default.
• W4225140897 cites W2043514521 @default.
• W4225140897 cites W2058074871 @default.
• W4225140897 cites W2075995611 @default.
• W4225140897 cites W2094438602 @default.
• W4225140897 cites W2100534360 @default.
• W4225140897 cites W2128300830 @default.
• W4225140897 cites W2146264128 @default.
• W4225140897 cites W2150959326 @default.
• W4225140897 cites W2161201373 @default.
• W4225140897 cites W2175231274 @default.
• W4225140897 cites W2312325623 @default.
• W4225140897 cites W2475261460 @default.
• W4225140897 cites W2555543235 @default.
• W4225140897 cites W2564078202 @default.
• W4225140897 cites W2583862987 @default.
• W4225140897 cites W2752734847 @default.
• W4225140897 cites W2775930384 @default.
• W4225140897 cites W2802245520 @default.
• W4225140897 cites W2885025259 @default.
• W4225140897 cites W2888543854 @default.
• W4225140897 cites W2888544493 @default.
• W4225140897 cites W2899764361 @default.
• W4225140897 cites W2900413769 @default.
• W4225140897 cites W2902455571 @default.
• W4225140897 cites W2936593438 @default.
• W4225140897 cites W2971414122 @default.
• W4225140897 cites W2974260792 @default.
• W4225140897 cites W2980072629 @default.
• W4225140897 cites W2989731764 @default.
• W4225140897 cites W3003318708 @default.
• W4225140897 cites W3003537357 @default.
• W4225140897 cites W3005251148 @default.
• W4225140897 cites W3008379265 @default.
• W4225140897 cites W3021572394 @default.
• W4225140897 cites W3081830235 @default.
• W4225140897 cites W3089283105 @default.
• W4225140897 cites W3094534128 @default.
• W4225140897 cites W3117441247 @default.
• W4225140897 cites W3138898349 @default.
• W4225140897 cites W3162195278 @default.
• W4225140897 cites W3175949331 @default.
• W4225140897 cites W3210322431 @default.
• W4225140897 cites W3212300867 @default.
• W4225140897 cites W4220977619 @default.
• W4225140897 cites W4238277289 @default.
• W4225140897 cites W4252004908 @default.
• W4225140897 doi "https://doi.org/10.3389/fcvm.2022.882181" @default.
• W4225140897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35571176" @default.
• W4225140897 hasPublicationYear "2022" @default.
• W4225140897 type Work @default.
• W4225140897 citedByCount "5" @default.
• W4225140897 countsByYear W42251408972022 @default.
• W4225140897 countsByYear W42251408972023 @default.
• W4225140897 crossrefType "journal-article" @default.
• W4225140897 hasAuthorship W4225140897A5001114263 @default.
• W4225140897 hasAuthorship W4225140897A5003828153 @default.
• W4225140897 hasAuthorship W4225140897A5025238832 @default.
• W4225140897 hasAuthorship W4225140897A5029430641 @default.
• W4225140897 hasAuthorship W4225140897A5038766995 @default.
• W4225140897 hasAuthorship W4225140897A5039171536 @default.
• W4225140897 hasAuthorship W4225140897A5060537275 @default.
• W4225140897 hasAuthorship W4225140897A5074831686 @default.
• W4225140897 hasBestOaLocation W42251408971 @default.
• W4225140897 hasConcept C126322002 @default.
• W4225140897 hasConcept C134018914 @default.
• W4225140897 hasConcept C159641895 @default.
• W4225140897 hasConcept C164705383 @default.
• W4225140897 hasConcept C17923572 @default.
• W4225140897 hasConcept C2777180221 @default.
• W4225140897 hasConcept C2777260377 @default.
• W4225140897 hasConcept C2777698277 @default.
• W4225140897 hasConcept C2778213512 @default.
• W4225140897 hasConcept C2910068830 @default.
• W4225140897 hasConcept C500558357 @default.
• W4225140897 hasConcept C555293320 @default.
• W4225140897 hasConcept C71924100 @default.
• W4225140897 hasConceptScore W4225140897C126322002 @default.
• W4225140897 hasConceptScore W4225140897C134018914 @default.
• W4225140897 hasConceptScore W4225140897C159641895 @default.
• W4225140897 hasConceptScore W4225140897C164705383 @default.
• W4225140897 hasConceptScore W4225140897C17923572 @default.
• W4225140897 hasConceptScore W4225140897C2777180221 @default.
• W4225140897 hasConceptScore W4225140897C2777260377 @default.

• next